BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7000388)

  • 1. Misonidazole in the clinic at Mount Vernon.
    Dische S
    Cancer Clin Trials; 1980; 3(2):175-8. PubMed ID: 7000388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical trials of hypoxic cell sensitizer misonidazole].
    Onoyama Y
    Gan No Rinsho; 1983 May; 29(6):718-25. PubMed ID: 6348345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD
    Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New side effect of the hypoxic cell sensitizer, misonidazole.
    Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC
    Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
    Hoskin PJ; Saunders MI; Dische S
    Cancer; 1999 Oct; 86(7):1322-8. PubMed ID: 10506720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials of misonidazole in the United States.
    Wasserman TH; Stetz J; Phillips TL
    Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. MRC working party on misonidazole in head and neck cancer.
    Br J Radiol; 1984 Jul; 57(679):585-95. PubMed ID: 6329395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experiences with the radiosensitizer Misonidazol (author's transl)].
    Bamberg M; Tamulevicius P; Streffer C; Scherer E
    Strahlentherapie; 1981 Aug; 157(8):524-36. PubMed ID: 7268822
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials with hypoxic cell sensitizers-the European experience.
    Dische S
    Prog Clin Biol Res; 1983; 132D():293-303. PubMed ID: 6356146
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.
    Coleman CN; Friedman MK; Jacobs C; Halsey J; Ignoffo R; Leibel S; Hirst VK; Gribble M; Carter SK; Phillips TL
    Cancer Res; 1983 Oct; 43(10):5022-5. PubMed ID: 6883348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postoperative radiotherapy of astrocytomas grade 3 and 4 with the radiosensitizer misonidazole. -End results of a multicentric controlled German study].
    Sack H; Calcanis A; Godehardt E; Weidtman V; Zülch KJ; Ammon J; Bamberg M; Herbst M; Keim H; Kleibel F; Makoski HB; Potthoff PC; Schlegel G; Schnepper E
    Strahlentherapie; 1982 Aug; 158(8):466-9. PubMed ID: 6753245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A national trial on the treatment of invasive bladder cancer.
    Arnold EP; Bailey C; Burry AF; Bydder PV; Firth LA; Gowland S; Gray AJ; Mcllroy R
    N Z Med J; 1981 Apr; 93(682):273-5. PubMed ID: 7019784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical testing of the radiosensitizer RO-07-0582 (misonidazole). Dose tolerance, toxicity and pharmacokinetic studies, preliminary report (author's transl)].
    Bataini JP; Bernier J; de Narbonne J; Brugère J; Jaulerry C; Brunin F
    Bull Cancer; 1978; 65(4):482-5. PubMed ID: 371710
    [No Abstract]   [Full Text] [Related]  

  • 14. Preliminary results of RTOG phase I/II study of misonidazole and radiation for bladder cancer.
    Mohiuddin M; Kramer S; Phillips T; Soberon M; Forgione H
    Am J Clin Oncol; 1982 Oct; 5(5):551-4. PubMed ID: 7180834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix. A report from the MRC Working Party on misonidazole for cancer of the cervix.
    Br J Radiol; 1984 Jun; 57(678):491-9. PubMed ID: 6372930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Present status of hypoxic cell sensitizers and PLDR inhibitors].
    Ono K; Sasai K; Shibamoto Y; Tsutsui K; Fushiki M; Nishidai T; Takahashi M; Abe M
    Gan No Rinsho; 1987 Oct; 33(13):1673-8. PubMed ID: 2961900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors.
    Overgaard J
    Oncol Res; 1994; 6(10-11):509-18. PubMed ID: 7620219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentrations of misonidazole.
    Notter G; Rylander U; Turesson I
    Strahlentherapie; 1980; 156(10):714-8. PubMed ID: 7434379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
    Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
    Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of misonidazole during continuous low dose rate irradiation.
    Fu KK; Hurst S; Begg AC; Brown JM
    Cancer Clin Trials; 1980; 3(3):257-65. PubMed ID: 7438323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.